Related Experiment Video

Updated: Aug 21, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.7K

Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies

Elisa Andrini1, Alessandro Di Federico1, Monia Sisi1

  • 1Department of Experimental, Diagnostic & Specialty Medicine (DIMES), Alma Mater Studiorum University of Bologna, Bologna, Italy.

Immunotherapy
|November 16, 2022
PubMed

Insights

Immunotherapy is transforming lung cancer treatment, but its role in rare non-small cell lung cancer (NSCLC) histologies and other thoracic malignancies needs further study. More research is essential for optimizing these rare tumor treatments.

Area of Science:

  • Oncology
  • Immunotherapy
  • Thoracic Malignancies

Background:

  • Immunotherapy has advanced non-small cell lung cancer (NSCLC) treatment.
  • The efficacy of immunotherapy in rare NSCLC histologies is not well-defined.
  • Immune checkpoint inhibitors are emerging as promising treatments for malignant pleural mesothelioma and thymic epithelial tumors.

Purpose of the Study:

  • To provide a comprehensive overview of immunotherapy's role in rare thoracic malignancies.
  • To highlight the need for further research in these "orphan tumors".

Main Methods:

  • Literature review of current immunotherapy applications in rare thoracic malignancies.
  • Analysis of existing data on immune checkpoint inhibitors in NSCLC with uncommon histologies, malignant pleural mesothelioma, and thymic epithelial tumors.

Main Results:

  • Immunotherapy shows promise but requires further investigation in rare thoracic malignancies.
  • Prospective studies are crucial for establishing optimal treatment strategies.
  • Current data suggests a changing therapeutic landscape for these rare tumors.

Conclusions:

  • The role of immunotherapy in rare thoracic malignancies is evolving.
  • Larger prospective studies are urgently needed to define treatment protocols.
  • Immunotherapy offers hope for improved outcomes in patients with these rare tumors.
Keywords:
NSCLCPD-(L)1 inhibitormalignant pleural mesotheliomarare histologiesthymic epithelial tumors

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

488
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

17.2K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
636
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K